Bli medlem
Bli medlem

Du är här


Elekta: GenesisCare continues to expand Spanishcancer services with Elekta

STOCKHOLM, October 25, 2016 - Elekta (EKTA-B.ST) announces that
GenesisCare will acquire Versa HD™ (
linear accelerators to help fulfil its ambition to improve cancer
care for patients in Spain. The deal also includes Elekta's MOSAIQ®
( oncology information system to
optimize the clinical care and operational efficiency of GenesisCare
in Spain.

Francois Pointurier, Elekta's Senior Vice President Region EMEA, says:
"Although we have seen an increase in the incidence of cancer in
Spain, the number of cancer deaths has fallen, thanks in part to
improved treatment using advanced radiation therapy devices. We are
proud to continue to partner with GenesisCare as they expand in Spain
and grow in the European market. GenesisCare will receive the most
advanced and recognized cancer treatment solutions on the market. We
look forward to providing the platforms to support GenesisCare's
vision to provide accurate, efficient and high quality treatment."

Following the recent acquisition of oncology groups, IMOncology and
Oncosur, GenesisCare is now the largest cancer care provider in

Dan Collins, Managing Director at GenesisCare, says: "By investing in
the latest technology and staff training we are providing our
patients with access to more efficient and effective care. This will
enable our physicians and staff to offer a smoother patient
experience and improve patient outcomes. The suite of advanced
technology solutions, global influence and commitment to innovation
offered by Elekta will support our shared efforts to improve cancer
services across Spain."

Versa HD is Elekta's most advanced linear accelerator, used to
accurately and quickly deliver radiation therapy. MOSAIQ is a
comprehensive oncology information system that centralizes
traditional radiation oncology, particle therapy and medical oncology
patient data into a single user interface, accessible by
multidisciplinary teams across multiple locations.

The total order is valued at EUR 25 million, of which approximately
EUR 9.5 million was booked in the second quarter of Elekta's fiscal
year. This agreement is in addition to an earlier deal with
GenesisCare announced on March 31, 2016

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta

Tel: +31 653 561 242, e-mail:
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail:
Time zone: CET: Central European Time
This information is information that Elekta AB (publ) is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication at 07:30 CET on October 25,

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,600 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on NASDAQ Stockholm. Website:

About GenesisCare
GenesisCare provides high quality specialist care to patients with
cancer and cardiovascular disease, the two largest disease burdens

The organisation exists to improve quality and access for patients and
communities in need. The group is the largest provider of
radiotherapy across Australia, operating 27 cancer centres in major
metropolitan and also regional settings (including in tertiary
teaching public hospitals). 80 locations provide cardiology or sleep
services. GenesisCare employs over 1700 highly trained health
professionals and support staff including more than 150 physicians
and leads, or participates, in approximately 100 clinical trials.

Cancer care is provided for all tumor groups with the latest
techniques including intensity modulated radiotherapy, volumetric arc
therapy, stereotactic radiotherapy and radiosurgery, low dose rate
and high dose rate brachytherapy.

The GenesisCare medical team is comprised of some of the world's most
experienced specialists with many dedicating time as consultants in
public hospitals or participating in research and teaching.
GenesisCare adopts internationally proven medical technologies
integrated with electronic healthcare records to improve patient
clinical outcomes and their service experience. Website:


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.